EVO Evotec: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Evotec Corp - graphic logo of issuer EVO

Evotec SE (EVO) attracts leading chemists and biologists due to its academic atmosphere and involvement in medical breakthroughs. The company's current EV/EBITDA level, based on data from the GURU.Markets chart, is fixed at 0.00. Growing demand for research outsourcing is expanding the client base, while financial success is driven by the utilization of bio-platforms and the receipt of milestone payments.

EVO (Evotec Corp) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/12/2026

EVO (evotec.com): analytical breakdowns and indicator data

- current price and projected stock value:
Stock Price Evotec Corp|EVO - Average Forecast Price
- company stock capitalization data:
Market Value Evotec Group|EVO - Company Buyout Price
- book value of equity indicators:
Accounting Value per Share Evotec|EVO - Total Net Assets|Market Value to Book Value Ratio evotec.com|EVO - Company Total Asset Base
- company liabilities and liquidity data:
Total Debt to Capital Evotec SE|EVO - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Evotec|EVO - Company Debts|Debt to Book Capitalization Ratio Evotec Group|EVO - Long-Term Debt|Company Current Liabilities Evotec|Quick Ratio evotec.com
- net income and valuation multiples indicators:
EVO - Company Net Income|Projected Future Earnings Evotec SE|EVO - Price to Earnings Ratio|Projected Price to Earnings Evotec SE|EVO - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Evotec Group|EVO - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Evotec|EVO - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth evotec.com|EVO - Earnings per share growth rate in current year|Expected earnings per share growth for next year Evotec SE
Summary company analytics:EVO (Evotec Corp)
Product sample of Evotec AG

Professional managers utilize fundamental filters to separate resilient assets from overvalued ones, assessing business value relative to earnings before interest, taxes, depreciation, and amortization. This metric measures the payback period of capital including debt, which, given the equipment modernization at Evotec SE and high laboratory utilization, allows the EV/EBITDA ratio trajectory to determine the real value of the company's technological leadership.

Competitor analysis

EV/EBITDA Multiple IQV (IQVIA Inc.)|LabCorp (LH) - Company Value to EBITDA|MEDP - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio ICON Public Limited Company ICLR|CRL (Charles River) - Enterprise Value to EBITDA Ratio|FTRE: Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lifecore Biomedical Inc.|OmniAb Inc (OABI) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple NOTV|CDMO - Company Value to EBITDA|Catalent - Enterprise Value to EBITDA Ratio|Scorpius Holdings Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization